6-氯-2-氟-3-甲氧基苯甲醛 | 112641-64-2

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 6-氯-2-氟-3-甲氧基苯甲醛
• 英文名称: 2-chloro-6-fluoro-5-methoxybenzaldehyde
• 英文别名: 6-chloro-2-fluoro-3-methoxybenzaldehyde；6-chloro-2-fluoro-3-methoxy-benzaldehyde
• CAS: 112641-64-2
• 化学式: C₈H₆ClFO₂
• mdl: MFCD04115946
• 分子量: 188.586
• InChiKey: OADUJQWBRPRPQX-UHFFFAOYSA-N

物化性质

• 熔点：
  95-100℃
• 沸点：
  264.9±35.0 °C(Predicted)
• 密度：
  1.334±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2913000090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

制备方法与用途

6-氯-2-氟-3-甲氧基苯甲醛主要用于科研作为研究用化合物。

反应信息

• 作为反应物：
  描述：

  6-氯-2-氟-3-甲氧基苯甲醛 在 硫酸 作用下， 以 乙腈 为溶剂， 反应 3.0h， 生成 1,2-bis(6-chloro-2-fluoro-3-methoxyphenyl)ethane-1,2-diamine
  参考文献：
  名称：

  Synthesis and evaluation of the anti-mammary tumor activity and of the estrogenic side effects of [1,2-bis(2,6-dihalo-3-hydroxyphenyl)ethylenediamine]platinum(II) complexes

  摘要：

  The synthesis and structural characterization of mammary tumor-inhibiting, diastereomeric [1,2-bis(2,6-dihalo-3-hydroxyphenyl) ethylenediamine]platinum(II) complexes with 2,6-Cl2, 2-F, 6-Cl, 2-Cl, 6-F and 2,6-F2 substituents (1-PtSO4 to 4-PtSO4) are described. The related 1,2-diphenylethylenediamines (1-4) are synthesized by stereoselective meso-meso and D,L-D,L diaza-Cope-rearrangement reactions and coordinated to platinum(II) with K2PtI4 (1-PtI2 to 4-PtI2). The subsequent reaction with Ag2SO4 leads to the respective sulfatoplatinum(II) complexes. They were tested for their anti-tumor activities on die hormone-sensitive and- insensitive MXT mammary carcinoma implanted in mice (MXT-MC, ER+ and MXT-MC, ER-). Complexes with F atoms in the neighborhood of the 3-hydroxy group showed strong inhibitory effects on the MXT-MC, ER+. The best effects were found for the diastereomeric 2,6-F2-substituted complexes, meso-4-PtSO4 and D,L-4-PtSO4. These complexes are strongly active both on the MXT-MC, ER+ and the MXT-MC, ER- and cause no estrogenic side effects.

  DOI：

  10.1016/0223-5234(93)90003-w
• 作为产物：
  描述：

  2-氟苯甲醚 在 仲丁基锂 、 氯 作用下， 以 溶剂黄146 为溶剂， 反应 4.25h， 生成 6-氯-2-氟-3-甲氧基苯甲醛
  参考文献：
  名称：

  Synthesis and evaluation of the anti-mammary tumor activity and of the estrogenic side effects of [1,2-bis(2,6-dihalo-3-hydroxyphenyl)ethylenediamine]platinum(II) complexes

  摘要：

  The synthesis and structural characterization of mammary tumor-inhibiting, diastereomeric [1,2-bis(2,6-dihalo-3-hydroxyphenyl) ethylenediamine]platinum(II) complexes with 2,6-Cl2, 2-F, 6-Cl, 2-Cl, 6-F and 2,6-F2 substituents (1-PtSO4 to 4-PtSO4) are described. The related 1,2-diphenylethylenediamines (1-4) are synthesized by stereoselective meso-meso and D,L-D,L diaza-Cope-rearrangement reactions and coordinated to platinum(II) with K2PtI4 (1-PtI2 to 4-PtI2). The subsequent reaction with Ag2SO4 leads to the respective sulfatoplatinum(II) complexes. They were tested for their anti-tumor activities on die hormone-sensitive and- insensitive MXT mammary carcinoma implanted in mice (MXT-MC, ER+ and MXT-MC, ER-). Complexes with F atoms in the neighborhood of the 3-hydroxy group showed strong inhibitory effects on the MXT-MC, ER+. The best effects were found for the diastereomeric 2,6-F2-substituted complexes, meso-4-PtSO4 and D,L-4-PtSO4. These complexes are strongly active both on the MXT-MC, ER+ and the MXT-MC, ER- and cause no estrogenic side effects.

  DOI：

  10.1016/0223-5234(93)90003-w

文献信息

• SULTAM DERIVATIVES
  申请人：Anderson Kevin W.

  公开号：US20110124686A1

  公开（公告）日：2011-05-26

  The present invention relates to compounds according to formula 1, which exhibit cytotoxic activity. The compounds may be used in the treatment of cancer.

  本发明涉及符合式1的化合物，具有细胞毒活性。这些化合物可用于治疗癌症。
• PYRAZOLOPYRIDINE PYRAZOLOPYRIMIDINE AND RELATED COMPOUNDS
  申请人：Global Blood Therapeutics, Inc.

  公开号：US20150315198A1

  公开（公告）日：2015-11-05

  In one aspect this invention relates generally to compounds of Formula: and sub-formulas thereof, or a tautomer of each thereof, a pharmaceutically acceptable salt of each thereof, or a pharmaceutically acceptable solvate of each of the foregoing, where X 1 , L 1 , L 3 , and R 3 are described herein.

  在一个方面，这项发明通常涉及以下式的化合物： 及其亚式，或每个亚式的重排异构体，每个的药学上可接受的盐，或每个前述的药学上可接受的溶剂，其中X 1 ，L 1 ，L 3 和R 3 如本文所述。
• Sultam derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US08314250B2

  公开（公告）日：2012-11-20

  The present invention relates to compounds according to formula 1, which exhibit cytotoxic activity. The compounds may be used in the treatment of cancer.

  本发明涉及公式1所示的化合物，其具有细胞毒性活性。该化合物可用于癌症治疗。
• Dihydropyridine derivatives, processes for their preparation and pharmaceutical compositions thereof
  申请人：FISONS plc

  公开号：EP0225175A2

  公开（公告）日：1987-06-10

  There are described compounds of Formula I, in which R₁, R₂, R₃ and R₄ are as defined in the specification, R₅ is alkyl optionally interrupted by an amide group and optionally substituted by halogen or by a carboxy or a heterocyclic group, X is -O-, -NR-, -S(O)m₁, or a bond, Z is hydrogen or together with R forms a bond, R is hydrogen, alkyl or together with Z forms a bond, R₆ is a 5 or 6 membered unsaturated nitrogen containing heterocyclic ring, optionally fused to a phenyl ring and optionally substituted by one or more of oxo, hydroxy, alkyl, -(CH₂)n₁NH₂, alkoxy, phenyl or -COOH, and when X is -NR- or -S(O)m₁-, R₆ may in addition be hydrogen or a group -CH₂CH₂NH₂, -CH₂CH₂-het. or NHC(=NH)NH₂, when X is -O-, R₆ may also be a group -NH₂, -C(=O) (CH₂)nNH₂, -CH₂CH₂NR₁₄R₁₅ or CH₂CH₂OCH₂CH₂NR₁₄R₁₅, when X is -NR-, -S(O)m₁-, or a bond, R₆ may also be hydrogen or a group -C(=NR₁₂)NHR₁₃, R₁₃ and R₁₄ may be hydrogen or alkyl, R₁₂ is hydrogen, alkylcarbonyl, nitrile or hydroxy, R₁₅ is hydrogen or a group R₁₁, m and m₁ are each 0, 1 or 2, n is 0 or 1, n₁ is an integer from 0 to 6 and pharmaceutically acceptable salts, esters, amides, analogues and protected derivatives thereof.

  所述化合物为式 I、 其中 R₁、R₂、R₃ 和 R₄ 如说明书中所定义、 R₅ 是任选被酰胺基打断并任选被卤素或羧基或杂环基取代的烷基、 X 是-O-、-NR-、-S(O)m₁ 或键、 Z 是氢，或与 R 形成键、 R 是氢、烷基或与 Z 共同形成键、 R₆ 是 5 或 6 个成员的不饱和含氮杂环，可选择与苯基环融合，并可选择被氧 化物、羟基、烷基、-(CH₂)n₁NH₂、烷氧基、苯基或-COOH 中的一个或多个取代、 当 X 为-NR-或-S(O)m₁-时，R₆ 还可以是氢或基团-CH₂CH₂NH₂、-CH₂CH₂-热或 NHC(=NH)NH₂ 、 当 X 为 -O- 时，R₆ 也可以是基团 -NH₂、-C(=O) (CH₂)nNH₂, -CH₂CH₂NR₁₄R₁₅ 或 CH₂CH₂OCH₂CH₂NR₁₄R₁₅、 当 X 为-NR-、-S(O)m₁- 或键时，R₆ 也可以是氢或基团-C(=NR₁₂)NHR₁₃、 R₁₃ 和 R₁₄ 可以是氢或烷基、 R₁₂ 是氢、烷基羰基、腈或羟基、 R₁₅ 是氢或基团 R₁₁、 m 和 m₁ 均为 0、1 或 2、 n 为 0 或 1、 n₁ 是 0 至 6 的整数 及其药学上可接受的盐、酯、酰胺、类似物和受保护的衍生物。
• Design and Application of a Low-Temperature Continuous Flow Chemistry Platform
  作者：James A. Newby、D. Wayne Blaylock、Paul M. Witt、Julio C. Pastre、Marija K. Zacharova、Steven V. Ley、Duncan L. Browne

  DOI：10.1021/op500213j

  日期：2014.10.17

  A flow reactor platform technology applicable to a broad range of low temperature chemistry is reported. The newly developed system captures the essence of running low temperature reactions in batch and represents this as a series of five flow coils, each with independently variable volume. The system was initially applied to the functionalization of alkynes, Grignard addition reactions, heterocycle functionalization, and heteroatom acetylation. This new platform has then been used in the preparation of a 20-compound library of polysubstituted, fluorine-containing aromatic substrates from a sequential metalation-quench procedure and can be readily adapted to provide gaseous electrophile inputs such as carbon dioxide using a tube-in-tube reactor.